Complete response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation
Metastatic pancreatic cancer (mPC) is usually diagnosed at an advanced stage, and systemic therapy is still the main treatment option. Pathological germline mutations in the BRCA1 or BRCA2 genes are present in aroun 4–7% of cases of pancreatic cancer (PC). The poly(adenosine diphosphate-ribose) poly...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Via Medica
2026-10-01
|
| سلاسل: | Oncology in Clinical Practice |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/106789 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|